French drugmaker Sanofi is cutting 466 jobs as part of an R&D “reshuffle” that will also put an end to the company’s new research efforts in cardiology, Reuters reports.
A spokesperson said on June 19 the reorganization of Sanofi’s R&D department will allow the company to concentrate its research efforts on cancer, immunology, rare diseases and vaccines. While that means Sanofi is putting a halt to any new research in cardiology, its existing CV research programs will remain intact.
The 466 job cuts will be implemented on a voluntary basis, according to Reuters. Right now, Sanofi employs 15,000 R&D workers worldwide.
Read the story below: